Angle PLC UKE publishes evaluation of Parsortix (8247M)
January 25 2016 - 02:00AM
UK Regulatory
TIDMAGL
RNS Number : 8247M
Angle PLC
25 January 2016
For immediate release 25 January 2016
ANGLE plc
("ANGLE" or "the Company")
PEER-REVIEWED PUBLICATION HIGHLIGHTS SIGNIFICANT ADVANTAGES OF
PARSORTIX(TM) IN HARVESTING CTCS OVER OTHER APPROACHES
Allows Harvesting of Cancer Cells From Blood With Exceptional
Purity And Viability Enabling Broad Range Of Molecular Analysis
Paper by University Medical Centre Hamburg-Eppendorf (UKE)
published in International Journal of Cancer
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, today announces that University Medical Centre
Hamburg-Eppendorf (UKE) has published an evaluation of ANGLE's
Parsortix(TM) system in the prestigious peer-reviewed International
Journal of Cancer. The paper is entitled "A novel microfluidic
platform for size and deformability based separation and the
subsequent molecular characterization of viable circulating tumor
cells" (1) .
The UKE cancer research centre is a world-leading authority on
the emerging field of liquid biopsy and, in 2015 alone, published
17 scientific papers in high ranking journals on different aspects
of the application of liquid biopsy in cancer care.
UKE's evaluation demonstrated significant advantages of the
Parsortix system in harvesting circulating tumour cells (CTCs)
compared to antibody-based and filtration CTC enrichment systems.
The publication determined that the Parsortix system enables the
harvesting of CTCs at a high purity and provides viable tumour
cells that are easily accessible and ready for a broad range of
molecular and functional analyses.
99 per cent of the harvested CTCs from both spiked and patient
samples were viable after processing and still functional for
downstream molecular analysis as demonstrated by mRNA
characterisation and array based comparative genomic
hybridisation.
Prof. Klaus Pantel, Chairman, Department of Tumour Biology at
UKE's Centre of Experimental Medicine, commented:
"Systems that can comprehensively capture the broad range of
CTCs - not only epithelial cells, but others including mesenchymal
cells - will play an important role in cancer diagnoses and
subsequent treatment. Our findings emphasise the importance of
developing new label-free assays that allow the molecular
characterisation of CTCs for therapeutic targets and resistance
mechanisms at the DNA, RNA and protein level. This information is
vital as liquid biopsies will help clinicians to adapt therapies to
the individual needs of cancer patients."
ANGLE's Founder and Chief Executive, Andrew Newland, added:
"This is our third peer-reviewed publication in a key scientific
journal and adds to the growing body of published evidence of
Parsortix's superior performance as a liquid biopsy. The
demonstration of viability of the CTCs is notable and in stark
contrast to competing approaches. Cell viability and easy
harvesting of cells from blood are key capabilities that
differentiate ANGLE's Parsortix system for the developing liquid
biopsy market in cancer diagnosis and treatment."
1. The publication is available for download at
http://www.angleplc.com/the-parsortix-system/download-files/
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher
Golden (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in the United States, Canada, China and Australia
and three extensive families of patents are being progressed
worldwide. The system is based on a microfluidic device that
captures cells based on a combination of their size and
compressibility. The Parsortix system is established with strong
positive evaluations from leading cancer research centres and is
working with these cancer centres to demonstrate key applications.
Parsortix has a CE Mark for Europe and FDA authorisation is in
process for the United States.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi $billion clinical market. The Parsortix system
is designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market. The product is on
the market and being sold for research use and work is progressing
towards approvals for clinical use to permit clinical sales of the
system.
ANGLE is strongly focused on establishing the use of the
Parsortix system in clinical practice. To achieve this, ANGLE has
established formal collaborations with world-class cancer centres.
These Key Opinion Leaders are working to identify applications with
medical utility (clear benefit to patients), and to secure clinical
data that demonstrates that utility in patient studies. ANGLE
believes this is the optimal approach for unlocking the
multi-billion dollar worldwide market available to the Company and
its potential strategic partners. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDDGDBIBDBGLS
(END) Dow Jones Newswires
January 25, 2016 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2023 to Mar 2024